T1	Participants 34 101	patients receiving androgen deprivation therapy for prostate cancer
T2	Participants 185 209	advanced prostate cancer
T3	Participants 356 410	patients with prostate cancer during androgen ablation
T4	Participants 494 518	advanced prostate cancer
T5	Participants 929 937	(n = 24)
T6	Participants 1072 1080	(n = 24)
